Related Experiment Videos
Effect of aurothiomalate on human mononuclear blood cells cultured in vitro
Abstract:
Human mononuclear phagocytes were exposed to aurothiomalate in various concentrations and at various stages in the differentiation from monocytes to macrophages in vitro. Monocytes exposed to aurothiomalate during the first 90 minutes of culture showed impaired engulfment capacity when tested 8 days after the exposure to the drug. It was found that aurothiomalate suppressed the digestion capacity in differentiated macrophages while the engulfment capacity was unaffected by the drug. During the period of differentiation from 90 minutes to 8 days of culture, exposure to aurothiomalate resulted in a dose dependent reduction in cell survival and differentiation. The effect of aurothiomalate on the blastoid transformation of lymphocytes following BCG stimulation was also tested. A strong and dose dependent inhibition of DNA synthesis was recorded. The inhibition of phagocytosis in mononuclear phagocytes and the inhibition of antigen-induced lymphocyte stimulation as demonstrated may help to explain the effect of aurothiomalate in patients suffering from rheumatoid arthritis.
Insights
Aurothiomalate impairs immune cell function in rheumatoid arthritis patients. Early exposure reduces phagocytosis, while later exposure affects cell survival and lymphocyte response, potentially explaining its therapeutic effects.
Area of Science:
- Immunology
- Pharmacology
- Cell Biology
Background:
- Aurothiomalate is a gold salt used in rheumatoid arthritis treatment.
- Its immunomodulatory effects are not fully understood.
- Understanding its impact on immune cells is crucial for explaining its therapeutic mechanisms.
Purpose of the Study:
- To investigate the effects of aurothiomalate on human mononuclear phagocytes and lymphocytes in vitro.
- To determine how drug exposure timing and concentration influence immune cell function.
- To correlate observed immune cell effects with potential mechanisms of action in rheumatoid arthritis.
Main Methods:
- Human monocytes were cultured in vitro and exposed to aurothiomalate at different concentrations and differentiation stages.
- Phagocytosis and digestion capacities of differentiated macrophages were assessed.
- Cell survival and differentiation were measured after drug exposure.
- Lymphocyte blastoid transformation following BCG stimulation was analyzed for DNA synthesis inhibition.
Main Results:
- Early exposure (first 90 minutes) of monocytes to aurothiomalate impaired subsequent phagocytosis.
- Differentiated macrophages showed suppressed digestion but unaffected engulfment after drug exposure.
- Exposure during differentiation (90 minutes to 8 days) caused dose-dependent reductions in cell survival and differentiation.
- Aurothiomalate strongly and dose-dependently inhibited DNA synthesis in BCG-stimulated lymphocytes.
Conclusions:
- Aurothiomalate significantly impacts mononuclear phagocyte function, including phagocytosis and digestion.
- The drug affects lymphocyte proliferation, indicating an immunomodulatory role.
- These observed effects on immune cells may elucidate the therapeutic mechanisms of aurothiomalate in rheumatoid arthritis treatment.